Olaf Stüve - Concepedia

Author

Olaf Stüve

The University of Texas Southwestern Medical Center ORCID

Also Known As

M. Racke, Maria Pia Sormani, O Stuve, O Stüve, O. Stuve, O. Stüve, O. Stüve, Olaf Stuve, Olaf Stüve, Olaf Stüve

374

Publications

21.1K

Citations

H-Index

113

Concepts

All Affiliations

The University of Texas Southwestern Medical Center VA North Texas Health Care System University of California, San Francisco Heinrich Heine University Düsseldorf

About

Olaf Stüve is an author at The University of Texas Southwestern Medical Center specializing in medicine, neuroimmunology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	36	7.6K
2	Health Sciences	3	3	1K
3	Public Health	3	3	3.1K
4	Allergy	3	3	101
5	Social Sciences	1	1	22

Olaf Stüve

100

Publications

11.7K

Citations

H-Index

Page 1

	Year	Citations
Defining the clinical course of multiple sclerosis Fred Lublin, Stephen C. Reingold, Jeffrey A. Cohen, Neurology Neuroimaging BiomarkersSclerodermaNeurological DiseaseDisease ProgressionMedicine	2014	3K
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease Sawsan Youssef, Olaf Stüve, Juan C. Patarroyo, Nature InflammationAutoimmune DiseaseDisease MechanismMedicineAutophagy	2002	1.1K
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study Ludwig Kappos, Amit Bar‐Or, Bruce Cree, The Lancet Neurological DisorderClinical NeurologyClinical TrialsSiponimod Versus PlaceboNeurological Monitoring	2018	896
Type II monocytes modulate T cell–mediated central nervous system autoimmune disease Martin S. Weber, Thomas Prod’homme, Sawsan Youssef, Nature Medicine ImmunologyImmune RegulationCd4 T Cell ResponsesImmune SystemType Ii	2007	445
Immune surveillance in multiple sclerosis patients treated with natalizumab Olaf Stüve, Christina M. Marra, Keith R. Jerome, Annals of Neurology	2006	434
Interferon β‐1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase‐9 Olaf Stüve, Nora P. Dooley, Joon H. Uhm, Annals of Neurology T-regulatory CellImmunologyImmunologic MechanismCd4 T Cell ResponsesImmunotherapy	1996	355
Altered CD4+/CD8+ T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis Olaf Stüve, Christina M. Marra, Amit Bar‐Or, Archives of Neurology	2006	270
Treatment of neuromyelitis optica: Review and recommendations Dorlan Kimbrough, Kazuo Fujihara, Anu Jacob, Multiple Sclerosis and Related Disorders Ocular DiseaseOphthalmologyOptic NeuropathyNeuromyelitis OpticaNeurology	2012	258
Factors that influence adherence with disease-modifying therapy in MS Katherine Treadaway, Gary Cutter, Amber Salter, Journal of Neurology Disease ManagementChronic Disease ManagementPatient SupportInfluence AdherenceMedicine	2009	257
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study Krzysztof Selmaj, David K.B. Li, Hans-Peter Hartung, The Lancet Neurology Relapsing-remitting Multiple SclerosisDisease ProgressionNeurological DisorderMedicineClinical Trials	2013	230

Page 1